#poct

[shivmehara]

Lactate Monitoring Devices Market Size, Share and Trends Report

Lactate Monitoring Devices Market Size Was Valued at USD 434.67 Million in 2023 and is Projected to Reach USD 901.29 Million by 2032, Growin

Lactate Monitoring Devices Market Size Was Valued at USD 434.67 Million in 2023 and is Projected to Reach USD 907.29 Million by 2032, Growing at a CAGR of 8.52% From 2024-2032.

[healthcare-updates]

Future of Diagnostics: Is POCT Becoming the New Standard of Care?

POCT is reshaping diagnostic practices with rapid, on-site testing. Learn how it’s changing patient care and redefining the diagnostic landscape.

As healthcare shifts toward speed and precision, Point-of-Care Testing (POCT) is quickly gaining traction as a frontline approach in diagnostics. With the ability to deliver rapid results near the patient, POCT minimizes delays in treatment decisions, particularly in emergency and remote settings.

Clinicians are now rethinking traditional lab-dependent processes. POCT provides immediate data that supports faster clinical decisions, leading to improved patient experiences and outcomes. From glucose monitors to portable PCR machines, the growing range of devices reflects its expanding role in care delivery.

The rising demand for decentralized testing, especially in pandemic scenarios, has further cemented POCT’s relevance. Its integration into primary care, ambulatory clinics, and even home settings signals a shift that’s hard to ignore.

While regulatory and quality control challenges persist, the industry is adapting quickly. As technology advances and clinical workflows adjust, POCT is positioned to become a key part of modern diagnostic strategies — no longer a supplement, but potentially the standard.

For insights on the future of elderly health tech, read the full article Here

[pathologylab]

Join us today at #ASHM #POC25 in Bangkok, #Thailand!

We're excited to showcase our groundbreaking Point-of-Care #testing #solutions that deliver rapid and cost-effective #diagnostics.

Visit us and learn more about our extensive menu of testing #kits and #equipment, and connect with us to find out how we can support your diagnostic #goals.

See you at the booth!

📍: Bangkok, Thailand

📅: June 19-21, 2025

🏪: #7

#g2m #genes2me #poc #poct #pointofcare #sepsis #patientcare #rapid #rtpcr

[pathologylab]

Join us at ASHM POC'25 in #Bangkok, #Thailand from June 19-21!

Discover our groundbreaking Point-of-Care testing solutions that deliver rapid and cost-effective #diagnostics.

Explore our extensive menu of #testing kits and equipment, and connect with our expert team to find out how we can support your diagnostic goals.

Let’s push the boundaries of what's possible in #POCT — see you at the booth!

To schedule a meeting or for more information, reach out to us at ✉[email protected] or 🌍 https://www.genes2me.com/upcoming-events

📍: Bangkok, Thailand

📅: June 19-21, 2025

🏪: #7

#conference #events #exhibition #visit #solutions #poc #pointofcare #rapid #kit #rtpcr #pcr #india #instruments #poc25

[market-insider]

U.S. Point-of-Care Molecular Diagnostics: Adoption Trends, Regulatory Landscape, Market Potential

The U.S. point-of-care molecular diagnostics market size was estimated at USD 3.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2030. The growth of the market is driven by rise in end-user awareness, along with the increased efficiency of the testing methods and favorability for non-laboratory testing. For instance, in the U.S., approximately 1% infants are diagnosed with congenital heart diseases (CHDs) every year. However, advancements in prenatal testing have led to rapid detection of genetic biomarkers in embryos, thus leading to early diagnosis of CHDs and other genetic disorders.

Market Concentration & Characteristics

Degree of Innovation: Market growth stage is low, and pace of market growth is accelerating. The U.S. point-of-care molecular diagnostics market is characterized by a moderate-to-high degree of innovation owing to the advancements in technology, including the introduction of next-generation sequencing (NGS)-friendly applications. Previously, POC testing has seen barriers in NGS testing, and market players as well as academic institutions have focused on relentless research and development efforts to overcome these.

Players in the point-of-care molecular diagnostics market leverage market strategies such as mergers, acquisitions, collaborations, and partnerships to promote reach of their offerings and increase their product capabilities in the region. For instance, in 2022, Bio-Rad Laboratories acquires Curiosity Diagnostics, integrating Curiosity’s rapid PCR system, PCR|ONE, to expand its presence in near-patient molecular diagnostics labs.

Key U.S. Point-of-Care Molecular Diagnostics Company Insights

Some of the key players operating in the U.S. point-of-care molecular diagnostics market include Abbott Laboratories; QIAGEN; F. Hoffman-La Roche Ltd; bioMerieux; and BD. Numerous key players are undertaking strategic initiatives such as expansion, product introductions, mergers, and acquisitions, while also focusing on increasing product reach in the U.S. Several market participants are investing in research and development initiatives, making the market susceptible to further growth. For More Details or Sample Copy please visit link @:U.S. Point-of-Care Molecular Diagnostics Market

[pathologylab]

#G2M is thrilled to announce that we will be participating in #ESCMID Global in Vienna, Austria from April 11-15!

Join us at booth no. #F60 to learn more about our innovative Point-of-Care #Testing solutions, #NGS clinical panels and RT-PCR solutions!

We are eager to showcase our latest advancements in #molecular diagnostics and share how our #products can enhance diagnostic #healthcare and transform patient outcomes.

We look forward to meeting you and sharing our groundbreaking work in molecular diagnostics! See you in Vienna!

📅 : April 11-14 2025

📌 : Messe Wien Exhibition Congress Center, Vienna, Austria

🏪 : Booth No. F60

🌍 : https://docs.google.com/forms/d/e/1FAIpQLScLIenx5L-sSLZhsvvrhp9cmlR1in6hWfbq5Em-hwKixVyIZw/viewform

#pointofcare #poc #poct #conference #exhibition #diagnostic #event #rtpcr #solution #poct #genes2me #escmidglobal #global #center #vienna #austria #congresscenter

[pathologylab]

#G2M was thrilled to be part of #MPAICON 2025, an inspiring event hosted by CMC Vellore, where innovation, #collaboration, and cutting-edge advancements took center stage!

With the theme “Advances in #Molecular Pathology: Bench to Bedside,” the #conference highlighted the latest breakthroughs in molecular #pathology and their impact on #clinical practice.

We had the opportunity to showcase our comprehensive portfolio of #NGS panels covering cancer biomarkers, exome sequencing, pathogen detection, and over 25 CE-IVD approved clinical panels. It was a pleasure engaging with industry leaders, exchanging insights, and exploring the future of #POCT solutions together.

A big thank you to everyone who visited our booth and shared valuable perspectives! Looking forward to more exciting conversations at upcoming events.

#genes2me #nextgenerationsequencing #success #advances #panel #cancer #exome #sequencing #exomesequencing #ivd #MPAICON2025 #MolecularPathology #Innovation #POC #Genomics #Healthcare

[wissenresearchllc]

The global market for point of care testing was valued at approximately USD 40.7 billion in 2023, and is projected to increase to USD 40.8 billion in 2025.